MAXHEALTH:NSE-Max Healthcare Institute Limited (INR)

COMMON STOCK | Medical Care Facilities | NSE

Last Closing Price

INR 431.05

Change

-5.10 (-1.17)%

Market Cap

INR 420.44B

Volume

2.32M

Avg Analyst Target

INR 470.00 (+9.04%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


MAXHEALTH Stock Forecast & Price:
Based on the Max Healthcare Institute Limited stock forecasts from 2 analysts, the average analyst target price for Max Healthcare Institute Limited is INR 470.00 over the next 12 months. Max Healthcare Institute Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Max Healthcare Institute Limited is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Max Healthcare Institute Limited’s stock price was INR 431.05. Max Healthcare Institute Limited’s stock price has changed by +1.11% over the past week, +1.46% over the past month and +18.11% over the last year.

About Max Healthcare Institute Limited (MAXHEALTH:NSE)

Max Healthcare Institute Limited provides healthcare services in India. It offers services in various specialties, including cancer care/oncology, cardiac sciences, neuro sciences, liver transplant and biliary sciences, orthopaedics, nephrology, kidney transplant, bone marrow tra ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
APOLLOHOSP:NSE Apollo Hospitals Enterprise Li..

-25.60 (-0.53%)

INR688.16B 81.95 31.54
FORTIS:NSE Fortis Healthcare Limited

+2.95 (+1.04%)

INR217.58B 42.95 18.83
NH:NSE Narayana Hrudayalaya Ltd.

-9.55 (-1.25%)

INR155.87B 34.59 18.77
KIMS:NSE Krishna Institute of Medical S..

-3.00 (-0.20%)

INR118.97B 38.31 21.66
MEDANTA:NSE Global Health Limited

-8.35 (-1.81%)

INR116.28B 51.61 22.16
ASTERDM:NSE Aster DM Healthcare Limited

+0.90 (+0.39%)

INR115.94B 23.47 10.40
RAINBOW:NSE Rainbow Childrens Medicare Lim..

-8.65 (-1.08%)

INR77.94B 61.13 27.15
HCG:NSE Healthcare Global Enterprises ..

+3.25 (+1.07%)

INR42.81B 55.19 22.50
MAXINDIA:NSE Max Healthcare Institute Limit..

N/A

INR18.42B 5.20 N/A
SHALBY:NSE Shalby Limited

+1.40 (+0.98%)

INR15.73B 20.17 10.98

ETFs Containing MAXHEALTH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Care Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.68% 30% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.68% 30% F 49% F
Trailing 12 Months  
Capital Gain 15.95% 67% D+ 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.95% 67% D+ 61% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.08% 22% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.08% 22% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 10.11% 100% A+ 98% A+
Risk Adjusted Return 50.26% 56% F 72% C-
Market Capitalization 420.44B 92% A- 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Care Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 44.35 42% F 24% F
Price/Book Ratio 5.98 46% F 18% F
Price / Cash Flow Ratio 56.17 17% F 14% F
EV/EBITDA 35.67 15% F 12% F
Management Effectiveness  
Return on Equity 14.66% 58% F 62% D-
Return on Invested Capital 8.68% 58% F 55% F
Return on Assets 5.77% 58% F 60% D-
Debt to Equity Ratio 10.02% 67% D+ 53% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.50 70% C- 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.